secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001213900-26-004382
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed to transfer POD platform to Lifeward for 49.9% beneficial ownership; invests $18M in convertible notes
--------------------------------------------------------------------------------

- Oramed to receive up to 49.9% beneficial ownership in Lifeward via shares, pre-funded warrants, plus 4% revenue sharing on ReWalk net sales (max 10 years).
- Oramed to invest $9M initial plus $9M milestone-based in 8% senior secured convertible notes convertible at $0.45/sh with 100% warrant coverage.
- Lifeward's ReWalk and AlterG products generated $26M revenue in trailing four quarters; CEO Mark Grant has 25+ yrs diabetes experience (Medtronic, BMS).
- Transaction requires Lifeward shareholder approval for >19.99% issuance; Oramed to manage clinical trial of oral insulin capsule.
- Combines Oramed's oral drug delivery platform with Lifeward's medical robotics; Oramed retains exposure to both platforms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026004382/0001213900-26-004382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390026004382/ea0272889-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-004382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer